Back

Kidney Function Decline, Heart Failure Hospitalization and the Effect of Empagliflozin in Heart Failure: An EMPEROR-Pooled Analysis

31 August 2026 (13:00 - 13:15)
Organised by: Logo
Congress Presentation Part of: Heart failure: the kidney is key Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Nicolas Girerd

University Hospital of Nancy, Nancy (France)

3 More presentations in this session

Presentation thumbnail
Glomerular filtration rate slope as a surrogate endpoint for kidney disease progression in heart failure trials: An individual participant data meta-analysis
Doctor M. Vaduganathan (Boston, US)
Presentation thumbnail
Predicting Short-term Effects on Blood Pressure, Kidney Function, and Serum Potassium with Heart failure Therapies and their Combinations
Doctor N. Wang (Sydney, AU)
Presentation thumbnail
Precision Phenotyping of Multi-Organ Fat Distribution Defines Distinct Cardiorenal-Metabolic and Heart Failure Risk Profiles
Doctor Y. Kway (Oxford, GB)

Access the full session

Session thumbnail
Heart failure: the kidney is key
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin in a real-world chronic heart failure population
3 September 2019
thumbnail
Congress Session
Late-breaking science in acute heart failure
19 May 2025
thumbnail
Webinar
Clinical trials and highlights from ACC 2024
10 April 2024
thumbnail
Congress Presentation
Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources